BEGIN:VCALENDAR VERSION:2.0 PRODID:-//ChamberMaster//Event Calendar 2.0//EN METHOD:PUBLISH X-PUBLISHED-TTL:P3D REFRESH-INTERVAL:P3D CALSCALE:GREGORIAN BEGIN:VEVENT DTSTART:20201119T170000Z DTEND:20201119T183000Z X-MICROSOFT-CDO-ALLDAYEVENT:FALSE SUMMARY:COVID Resilient Environment and Clinical Trials DESCRIPTION:Our panelists will explore how COVID-19 has affected clinical trials\, with an emphasis on how trials are successfully decentralizing. We'll hear from a clinical research organization with focus on using digital health\, novel trial modes\, and patient networks and engagement for how a virtual trial can work practically\; an attorney connected to the FDA regulation of clinical trials\; a gene therapy company with an ongoing clinical trial\; and a large pharma manufacturer with years of clinical experience in both vaccines and treatments. \n\n Phil Collis\, Ph.D.\, vice President\, global development\, BioCryst Pharmaceuticals (moderator)\n Amy Cramer\, director\, global product development strategic partnerships\, Pfizer\n Tina Papagiannopoulos\, associate\, Foley Hoag \n Kristen Pappas\, associate director\, bluebird bio \n David Tripi\, vice president\, innovation and customer engagement\, IQVIA\n\nThanks to our sponsors\, BIO and IQVIA Biotech. X-ALT-DESC;FMTTYPE=text/html:Our panelists will explore how COVID-19 has affected clinical trials\, with an emphasis on how trials are successfully decentralizing. We&rsquo\;ll hear from a clinical research organization with focus on using digital health\, novel trial modes\, and patient networks and engagement for how a virtual trial can work practically\; an attorney connected to the FDA regulation of clinical trials\; a gene therapy company with an ongoing clinical trial\; and a large pharma manufacturer with years of clinical experience in both vaccines and treatments. \;\n